公开(公告)号：US20160334419A1

公开(公告)日：2016-11-17

申请号：US15220555

申请日：2016-07-27

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Hans-Peter Brunner ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Thomas Dieterle ,  Cheryl Mitchell ,  Johan Ubby ,  Sandra Sanders-van Wijk

IPC: G01N33/68 ,  G01N33/72 ,  G01N33/84 ,  G01N33/66 ,  G01N33/62 ,  G01N33/70

Abstract: The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives BNP-type peptide guided heart failure therapy. Further envisaged by the present invention are kits and devices adapted to carry out the present invention.

Abstract translation: 本发明涉及一种用于识别符合心力衰竭治疗强化的患者的方法。 此外，本发明涉及一种优化BNP型肽引导性心力衰竭治疗的方法。 该方法基于来自患有心力衰竭并且接受​​BNP型肽引导的心力衰竭治疗的患者的样品中至少一个标记物的水平的测量。 本发明进一步设想的是适用于实施本发明的试剂盒和装置。

公开(公告)号：US10684291B2

公开(公告)日：2020-06-16

申请号：US15220555

申请日：2016-07-27

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Hans-Peter Brunner ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Thomas Dieterle ,  Cheryl Mitchell ,  Johan Ubby ,  Sandra Sanders-van Wijk

IPC: G01N33/53 ,  G01N33/68 ,  G01N33/62 ,  G01N33/66 ,  G01N33/70 ,  G01N33/72 ,  G01N33/84

Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.

公开(公告)号：US12117454B2

公开(公告)日：2024-10-15

申请号：US16868644

申请日：2020-05-07

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Hans-Peter Brunner ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Thomas Dieterle ,  Cheryl Mitchell ,  Johan Ubby ,  Sandra Sanders-van Wijk

IPC: G01N33/543 ,  G01N33/62 ,  G01N33/66 ,  G01N33/68 ,  G01N33/70 ,  G01N33/72 ,  G01N33/84

CPC classification number: G01N33/6893 ,  G01N33/62 ,  G01N33/66 ,  G01N33/6869 ,  G01N33/6887 ,  G01N33/70 ,  G01N33/723 ,  G01N33/84 ,  G01N2333/4737 ,  G01N2333/5412 ,  G01N2333/58 ,  G01N2333/78 ,  G01N2333/805 ,  G01N2800/325 ,  G01N2800/347 ,  G01N2800/52

Abstract: Methods for identifying a patient who is eligible for an intensification of heart failure therapy are disclosed. Furthermore, methods for optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy are disclosed. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described methods.

公开(公告)号：US20200271670A1

公开(公告)日：2020-08-27

申请号：US16868644

申请日：2020-05-07

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Hans-Peter Brunner ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Thomas Dieterle ,  Cheryl Mitchell ,  Johan Ubby ,  Sandra Sanders-van Wijk

IPC: G01N33/68 ,  G01N33/62 ,  G01N33/66 ,  G01N33/70 ,  G01N33/72 ,  G01N33/84

Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for pikej3optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.